dm+d

Unassigned

New Medicines

VyzultaGlaucoma; or ocular hypertension

Information

Vyzulta
New molecular entity
Bausch & Lomb
Bausch & Lomb

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Launched

Dec 17: Launched in the US [13]

Category

A novel nitric oxide-donating prostaglandin F2-alpha analogue
31 January 2013Primary open angle glaucoma (POAG) occurs in about 2% of people over 40 and 10% of those over 75 with a total of 480,000 affected individuals in England. Ocular hypertension is estimated to affect 3-5% of individuals aged over 40; about one million people in England. It is a major risk factor for the development of glaucoma [3].
Glaucoma; or ocular hypertension
Topical

Evidence based evaluations